| 50.21 -2.12 (-4.05%) | 01-26 12:57 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 62.82 | 1-year : | 73.37 |
| Resists | First : | 53.78 | Second : | 62.82 |
| Pivot price | 43.72  |
|||
| Supports | First : | 42.69 | Second : | 35.84 |
| MAs | MA(5) : | 49.99 |
MA(20) : | 43.05 |
| MA(100) : | 38.85 |
MA(250) : | 27.74 |
|
| MACD | MACD : | 2.5 |
Signal : | 1.3 |
| %K %D | K(14,3) : | 89 |
D(3) : | 94 |
| RSI | RSI(14): 65.6 |
|||
| 52-week | High : | 53.78 | Low : | 13.36 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ DNTH ] has closed below upper band by 20.3%. Bollinger Bands are 143.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 53.83 - 54.1 | 54.1 - 54.28 |
| Low: | 50.83 - 51.19 | 51.19 - 51.41 |
| Close: | 51.82 - 52.36 | 52.36 - 52.7 |
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
Mon, 26 Jan 2026
Dianthus Therapeutics (DNTH) Is Up 18.7% After Claseprubart Trial Progress Reshapes Its Autoimmune Focus - simplywall.st
Fri, 23 Jan 2026
Dianthus Therapeutics, Inc. (DNTH) Stock Analysis: Exploring a Potential 23% Upside in the Biotech Sector - DirectorsTalk Interviews
Fri, 23 Jan 2026
Dianthus Therapeutics, Inc. (DNTH) Moves 9.9% Higher: Will This Strength Last? - Nasdaq
Thu, 22 Jan 2026
Dianthus Therapeutics (NASDAQ:DNTH) Trading Up 10.3% - What's Next? - MarketBeat
Tue, 20 Jan 2026
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 12-Month High - Should You Buy? - MarketBeat
Tue, 20 Jan 2026
Dianthus Therapeutics stock hits 52-week high at 46.6 USD - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 43 (M) |
| Held by Insiders | 3.759e+007 (%) |
| Held by Institutions | 3.3 (%) |
| Shares Short | 3,710 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.402e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -10 % |
| Return on Assets (ttm) | 173.7 % |
| Return on Equity (ttm) | -18.9 % |
| Qtrly Rev. Growth | 3.08e+006 % |
| Gross Profit (p.s.) | -64.93 |
| Sales Per Share | -22.68 |
| EBITDA (p.s.) | 2.44444e+006 |
| Qtrly Earnings Growth | -3.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -110 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -2.22 |
| Price to Cash Flow | 4.96 |
| Dividend | 0 |
| Forward Dividend | 6.14e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|